Encompass Health (EHC) Raises Its Dividend, Is The Stock Fully Priced?
Dividend increase puts Encompass Health in focus
Encompass Health (EHC) has come into focus after its board approved a $0.02 increase in the quarterly dividend, setting a $0.21 per share payment scheduled for October 15, 2026.
See our latest analysis for Encompass Health.
Encompass Health's recent dividend increase comes as the stock trades at $112.89, with a 30 day share price return of 10.41% and a 5 year total shareholder return of 79.38%, suggesting momentum has supported long term holders.
If this kind of steady compounding appeals to you, it may be worth scanning for other healthcare stocks using advanced technology, including 39 healthcare AI stocks
After a sharp 30-day gain and a richer dividend, Encompass Health is drawing attention. Does it make more sense to commit capital at this level, or to wait for a cheaper entry before the numbers are unpacked?
Most Popular Narrative: 13.8% Overvalued
According to the most followed narrative for Encompass Health, the fair value estimate of $99.17 sits below the recent $112.89 share price, which raises questions about how much optimism is already priced in.
The broader healthcare industry is shifting from volume to value. Hospitals and rehabilitation providers are being evaluated not just on how many patients they treat, but on how well those patients recover and whether they avoid readmission. That dynamic creates a clear financial incentive to improve long term outcomes rather than simply manage short term stabilization.
Read the complete narrative. Read the complete narrative.
The fair value call here is not just a spreadsheet exercise. It rests on specific expectations for revenue growth, earnings trajectories and margins in a value based care world. This raises questions about how those moving parts combine to support a lower fair value than the current share price, and what that implies for Encompass Health at $112.89.
Result: Fair Value of $99.17 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Encompass Health still faces risks from reimbursement changes and any slowdown in its 7.6% revenue growth or 9.6% net income growth that could challenge earnings assumptions.
Find out about the key risks to this Encompass Health narrative.
Another view on Encompass Health's value
That 13.8% overvaluation call contrasts with how Encompass Health screens on earnings. At $112.89, the stock trades on a P/E of 18.9x, compared with 25.5x for the US healthcare industry, a peer average of 18.3x, and a fair ratio of 23.4x that the market could move towards.
In plain terms, the market is paying less for each dollar of Encompass Health earnings than the wider industry and less than the fair ratio suggests, but slightly more than close peers. That mix points to different types of valuation risk and opportunity, depending on which benchmark you trust most.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on value and expectations around Encompass Health, it helps to look under the hood yourself and move promptly from headline to conviction. To weigh the upside against the concerns in one place, start by reviewing the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Encompass Health?
If you stop at Encompass Health, you could miss out on other compelling setups, so take a few minutes to scan fresh ideas with the Simply Wall St screener.
- Spot potential bargains early by checking companies that combine quality and attractive pricing through the 49 high quality undervalued stocks.
- Strengthen your income toolkit by reviewing stocks that offer solid yields and payout profiles inside the 9 dividend fortresses.
- Prioritise resilience by focusing on companies with robust finances using the solid balance sheet and fundamentals stocks screener (49 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com